#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Current perspectives on the aetiology of tall stature in children and adolescents (2): Non-syndromic tall stature


Authors: Adamovičová Kateřina;  Plachý Lukáš;  Lebl Jan;  Koloušková Stanislava;  Průhová Štěpánka
Authors‘ workplace: 2. lékařská fakulta Univerzity ;  Karlovy a Fakultní nemocnice, v Motole ;  Pediatrická klinika
Published in: Čes-slov Pediat 2022; 77 (Supplementum 3): 18-23.
Category: Comprehensive Report
doi: https://doi.org/10.55095/CSPediatrie2022/054

Overview

Non-syndromic tall stature can be caused by growth hormone overproduction, hyperthyroidism, obesity, hypogonadism, precocious puberty or as constitutional growth acceleration. There are conditions caused by a genetic cause as well such as non-sydromic tall stature, typically familial tall stature or, more rarely, pituitary gigantism, which includes X-linked acrogigantism (XLAG). Tall stature can rarely occur in neurofibromatosis type I or in glucocorticoid resistance. After excluding the common endocrinopathies the patients are, in clinical practice, assigned as “familial tall stature” or “constitutional growth acceleration”. Recently, there have been findings showing that non-syndromic tall stature can be caused by a monogenic cause, which can only be found by detailed genetic testing with precise clinical-genetic evaluation. 

Keywords:

tall stature – growth hormone overproduction – FIPA – XLAG – familial tall stature


Sources
  1. Meazza C, Gertosio C, Giacchero R, et al. Tall stature: a difficult diagnosis? Ital J Pediatr 2017;43(1):66.
  2. Albuquerque E, Scalco RC, Jorge A. Management of endocrine disease: Diagnostic and therapeutic approach of tall stature. Eur J Endocrinol 2017; 176(6): 339–353.
  3. Leung AKC, Leung AAC, Hon KL. Tall stature in children. Adv Pediatr 2019; 66: 161–176.
  4. Wei C, Gregory JW. Physiology of normal growth. Paediatrics Child Health 2009; 19(5): 236–240.
  5. Baron J, Sävendahl L, De Luca F, et al. Short and tall stature: a new paradigm emerges. Nat Rev Endocrinol 2015; 11(12): 735–746.
  6. Lazarus JE, Hegde A, Andrade AC, et al. Fibroblast growth factor expression in the postnatal growth plate. Bone 2007; 40(3): 577–586.
  7. Liu Z, Lavine KJ, Hung IH, Ornitz DM. FGF18 is required for early chondrocyte proliferation, hypertrophy and vascular invasion of the growth plate. Dev Biol 2007; 302(1): 80–91.
  8. Mancilla EE, De Luca F, Uyeda JA, et al. Effects of fibroblast growth factor-2 on longitudinal bone growth. Endocrinology 1998; 139(6): 2900–2904.
  9. Hung IH, Yu K, Lavine KJ, Ornitz DM. FGF9 regulates early hypertrophic chondrocyte differentiation and skeletal vascularization in the developing stylopod. Developmen Biol 2007; 307(2): 300–313.
  10. Nilsson O, Parker EA, Hegde A, et al. Gradients in bone morphogenetic protein–related gene expression across the growth plate. J Endocrinol 2007; 193(1): 75–84.
  11. De Luca F, Barnes KM, Uyeda JA, et al. Regulation of growth plate chondrogenesis by bone morphogenetic protein-2. Endocrinology 2001; 142(1): 430–436.
  12. Hannema SE, van Duyvenvoorde HA, Premsler T, et al. An activating mutation in the kinase homology domain of the natriuretic peptide receptor-2 causes extremely tall stature without skeletal deformities. J Clin Endocrinol Metab 2013; 98(12): 1988–1998.
  13. Miura K, Kim OH, Lee HR, et al. Overgrowth syndrome associated with a gain–of–function mutation of the natriuretic peptide receptor 2 (NPR2) gene. Am J Med Genet A 2014; 164 A (1): 156–163.
  14. Chan Y, Holmen OL, Dauber A, et al. Common variants show predicted polygenic effects on height in the tails of the distribution, except in extremely short individuals. PLoS Genet 2011; 7(12): e1002439.
  15. Plachy L, Dusatkova P, Maratova K, et al. Familial short stature—a novel phenotype of growth plate collagenopathies. J Clin Endocrinol Metabolism 2021; 106(6): 1742–1749.
  16. Corredor B, Dattani M, Gertosio C, Bozzola M. Tall stature: a challenge for clinicians. Curr Pediatr Rev 2019; 15(1): 10–21.
  17. Vasilev V, Daly AF, Trivellin G, et al. Hereditary endocrine tumours: current state-of-the-art and research opportunities: The role of AIP and GPR101 in familial isolated pituitary adenomas (FIPA ). Endocr Rel Cancer 2020; 27(8): T77–T86.
  18. Beckers A, Petrossians P, Hanson J, Daly AF. The causes and consequences of pituitary gigantism. Nat Rev Endocrinol 2018; 14(12): 705–720.
  19. Cannavo S, Ragonese M, Puglisi S, et al. Acromegaly is more severe in patients with AHR or AIP gene variants living in highly polluted areas. J Clin Endocrinol Metab 2016; 101(4): 1872–1879.
  20. Daly AF, Lysy PA , Desfilles C, et al. GHRH excess and blockade in X–LAG syndrome. Endocr Rel Cancer 2016; 23(3): 161–170.
  21. Beckers A, Lodish MB, Trivellin G, et al. X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocr Rel Cancer 2015; 22(3): 353–367.
  22. Pagani S, Radetti G, Meazza C, Bozzola M. Analysis of growth hormone receptor gene expression in tall and short stature children. J Pediatr Endocrinol Metab 2017; 30(4): 427–430.
  23. Carmi D, Shohat M, Metzker A, Dickerman Z. Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study. Pediatrics 1999; 103(6): 1257–1262.
  24. Meimaridou E, Hughes CR, Kowalczyk J, et al. Familial glucocorticoid deficiency: New genes and mechanisms. Mol Cell Endocrinol. 2013; 371(1–2): 195–200.
  25. Savage MO, Lebrethon MC, Blair JC, et al. Growth abnormalities associated with adrenal disorders and their management. Horm Res 2001; 56 Suppl 1: 19–23.
Labels
Neonatology Paediatrics General practitioner for children and adolescents
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#